Who are Cullinan Therapeutics, Inc.'s main suppliers?

Cullinan Therapeutics, Inc. (CGEM) key suppliers include: CONTRACT-MANUFACTURING-ORGANIZATIONS, CONTRACT-RESEARCH-ORGANIZATIONS, VENDORS, Fate Therapeutics, Inc., IN8bio, Inc.. View the full supplier network at chainsifter.com/chain/CGEM.

Who are Cullinan Therapeutics, Inc.'s major customers?

Cullinan Therapeutics, Inc. (CGEM) key customers include: TAIHO, TAIHO-AFFILIATE, Fate Therapeutics, Inc., IN8bio, Inc.. View the full customer network at chainsifter.com/chain/CGEM.

What sector is Cullinan Therapeutics, Inc. in?

Cullinan Therapeutics, Inc. (CGEM) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

CGEM Supply Chain: Cullinan Therapeutics, Inc. Supplier List & 11 Relationships

5Suppliers

4Customers

2Debt Items

20Related Chains

Cullinan Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CONTRACT-MANUFACTURING-ORGANIZATIONS	CONTRACT-MANUFACTURING-ORGANIZATIONS	90%	The Company enters into contracts in the normal course of business with contract research organizations, contract manufacturing organizations, and other third parties for preclinical research studies…
CONTRACT-RESEARCH-ORGANIZATIONS	CONTRACT-RESEARCH-ORGANIZATIONS	90%	The Company enters into contracts in the normal course of business with contract research organizations, contract manufacturing organizations, and other third parties for preclinical research studies…
VENDORS	VENDORS	85%	In addition, we enter into agreements in the normal course of business with CROs for clinical trials and with other vendors for preclinical studies, manufacturing services, and other services and pro…
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: Reciprocal relationship from CGEM graph: Reciprocal relationship from FATE graph: Reciprocal relationship from CGEM graph: Reciprocal relationship from FATE g…
INAB	IN8bio, Inc.	72%	Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…

Cullinan Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
TAIHO	TAIHO	90%	We have received $275.0 million in revenue from a previous license agreement and cash proceeds of $18.9 million from the sale of our equity interest in our former zipalertinib development subsidiary …
TAIHO-AFFILIATE	TAIHO-AFFILIATE	90%	Pursuant to our co-development agreement, we are collaborating with a Taiho affiliate to develop zipalertinib for the treatment of a genetically defined subset of patients with NSCLC, and Taiho will …
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: ce with the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adve…
INAB	IN8bio, Inc.	72%	Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…

Cullinan Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CGEM-DEBT	Debt stack $2.4M	90%	Market cache reports total debt of $2.4M.
CGEM-DEBT-8611	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2022-09-30.

Cullinan Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Cullinan Therapeutics, Inc..

Cullinan Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
CGEM-OWNER-LYNX1-CAPITAL-MANAGEMENT-LP	Lynx1 Capital Management LP	90%	13F overlay lists Lynx1 Capital Management LP as top holder; 174 tracked holders.

Cullinan Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
VERA	Vera Therapeutics, Inc.	100.00	2
INAB	IN8bio, Inc.	100.00	1	['customer', 'supplier']
FATE	Fate Therapeutics, Inc.	100.00	1	['customer', 'supplier']
ALMS	Alumis Inc.	100.00	2
JBIO	Jade Biosciences, Inc.	100.00	2
TKPHF	Takeda Pharmaceutical Company Limited	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2
RCUS	Arcus Biosciences, Inc.	100.00	2
JNJ	Johnson & Johnson	100.00	2
KYTX	Kyverna Therapeutics, Inc.	100.00	2
BDTX	Black Diamond Therapeutics, Inc.	100.00	2
ZBIO	Zenas BioPharma, Inc.	100.00	2
VRTX	Vertex Pharmaceuticals Incorporated	100.00	2
TAIHO	TAIHO	60.75	1	['receiving']
ALLIST	ALLIST	50.00	2
CELG-RI	BRISTOL MYERS SQUIBB CO	50.00	2
EDIT	Editas Medicine, Inc.	50.00	2
REGN	Regeneron Pharmaceuticals, Inc.	50.00	2
ALLO	Allogene Therapeutics, Inc.	50.00	2
ADAPY	Adaptimmune Therapeutics PLC	50.00	2

Cullinan Therapeutics, Inc. Supply Chain